BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang SH, Suh K, Lee HW, Cho E, Cho JY, Cho YB, Yi N, Lee KU. The role of18F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-60. [DOI: 10.1002/lt.20861] [Cited by in Crossref: 112] [Cited by in F6Publishing: 102] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu HB, Wang QS, Li BY, Li HS, Zhou WL, Wang QY. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med. 2011;36:1092-1097. [PMID: 22064078 DOI: 10.1097/rlu.0b013e3182335df4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
2 Detry O, Govaerts L, Deroover A, Vandermeulen M, Meurisse N, Malenga S, Bletard N, Mbendi C, Lamproye A, Honoré P, Meunier P, Delwaide J, Hustinx R. Prognostic value of 18F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol 2015; 21(10): 3049-3054 [PMID: 25780305 DOI: 10.3748/wjg.v21.i10.3049] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
3 Yi N, Suh K, Suh S, Chang YR, Hong G, Yoo T, Kim H, Park MS, Choi YR, Lee K, Jung C, Lee JH, Kim YJ, Yoon J, Lee H. Excellent Outcome in 238 Consecutive Living Donor Liver Transplantations Using the Right Liver Graft in a Large Volume Single Center. World J Surg 2013;37:1419-29. [DOI: 10.1007/s00268-013-1976-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
4 Yun M, Bang SH, Kim JW, Park JY, Kim KS, Lee JD. The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma. J Nucl Med. 2009;50:1222-1228. [PMID: 19617323 DOI: 10.2967/jnumed.109.062703] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
5 Ho CL, Chen S, Cheung SK, Leung TWT. Significant Value of 11C-Acetate and 18F-Fluorodeoxyglucose PET/Computed Tomography on 90Y Microsphere Radioembolization for Hepatocellular Carcinoma. PET Clinics 2019;14:459-67. [DOI: 10.1016/j.cpet.2019.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22(1): 232-252 [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
7 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
8 Lee SD, Kim SH. Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2016;5:408-414. [PMID: 27826555 DOI: 10.21037/hbsn.2016.08.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
9 Lee JY, Kim YH, Yi NJ, Kim HS, Lee HS, Lee BK, Kim H, Choi YR, Hong G, Lee KW. Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol. 2014;20:192-203. [PMID: 25032186 DOI: 10.3350/cmh.2014.20.2.192] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
10 Shin D, Han S, Oh D, Im S, Kim T, Bang Y. Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. Cancer Chemother Pharmacol 2011;68:165-75. [DOI: 10.1007/s00280-010-1454-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
11 Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol 2016; 22(12): 3325-3334 [PMID: 27022214 DOI: 10.3748/wjg.v22.i12.3325] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
12 Lee JE, Jang JY, Jeong SW, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Jin SY, Choi DL. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J Gastroenterol 2012; 18(23): 2979-2987 [PMID: 22736922 DOI: 10.3748/wjg.v18.i23.2979] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
13 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
14 Miller G, Schwartz LH, D'Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am. 2007;16:343-368. [PMID: 17560517 DOI: 10.1016/j.soc.2007.04.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
15 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 29.2] [Reference Citation Analysis]
16 Hong G, Suh KS, Suh SW, Yoo T, Kim H, Park MS, Choi Y, Paeng JC, Yi NJ, Lee KW. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol. 2016;64:852-859. [PMID: 26658686 DOI: 10.1016/j.jhep.2015.11.033] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
17 Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912-1921. [PMID: 18997056 DOI: 10.2967/jnumed.108.055087] [Cited by in Crossref: 169] [Cited by in F6Publishing: 139] [Article Influence: 12.1] [Reference Citation Analysis]
18 Cheung TT, Chan SC, Ho CL, Chok KS, Chan AC, Sharr WW, Ng KK, Poon RT, Lo CM, Fan ST. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transpl. 2011;17:1218-1225. [PMID: 21688383 DOI: 10.1002/lt.22362] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
19 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
20 Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. J Nucl Med. 2013;54:1710-1716. [PMID: 23970365 DOI: 10.2967/jnumed.112.119370] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
21 Wang XY, Chen D, Zhang XS, Chen ZF, Hu AB. Value of 18F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound. J Dig Dis. 2013;14:433-438. [PMID: 23615075 DOI: 10.1111/1751-2980.12064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
22 Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25(11): 1289-1306 [PMID: 30918424 DOI: 10.3748/wjg.v25.i11.1289] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
23 Lee KW, Suh SW, Choi Y, Jeong J, Yi NJ, Kim H, Yoon KC, Hong SK, Kim HS, Lee KB, Suh KS. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation. Liver Transpl. 2017;23:19-27. [PMID: 27540701 DOI: 10.1002/lt.24610] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
24 Hoogenboom TC, Thursz M, Aboagye EO, Sharma R. Functional imaging of hepatocellular carcinoma. Hepat Oncol 2016;3:137-53. [PMID: 30191034 DOI: 10.2217/hep-2015-0005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Gauthé M, Richard-Molard M, Cacheux W, Michel P, Jouve JL, Mitry E, Alberini JL, Lièvre A; Fédération Francophone de Cancérologie Digestive (FFCD). Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis 2015;47:443-54. [PMID: 25766918 DOI: 10.1016/j.dld.2015.02.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
27 Talbot J, Michaud L, Grange J, Rosmorduc O, Balogova S. Use of choline PET for studying hepatocellular carcinoma. Clin Transl Imaging 2014;2:103-13. [DOI: 10.1007/s40336-014-0055-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
28 Lee JD, Kang WJ, Yun M. Primary Cancer of the Liver and Biliary Duct. PET Clin 2008;3:169-86. [PMID: 27156461 DOI: 10.1016/j.cpet.2008.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
29 Lovinfosse P, Hustinx R. Nuclear medicine techniques in transplantation. Clin Transl Imaging 2017;5:45-62. [DOI: 10.1007/s40336-016-0216-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kornberg A, Freesmeyer M, Bärthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D, Settmacher U. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009;9:592-600. [PMID: 19191771 DOI: 10.1111/j.1600-6143.2008.02516.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 116] [Article Influence: 8.9] [Reference Citation Analysis]
31 Kwong A, Mehta N. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis 2021;25:19-33. [PMID: 33978578 DOI: 10.1016/j.cld.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Lee HW, Suh KS. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant. 2016;21:231-237. [PMID: 26918880 DOI: 10.1097/mot.0000000000000294] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
33 Ortega López N. PET/Computed Tomography in Evaluation of Transarterial Chemoembolization. PET Clin 2015;10:507-17. [PMID: 26384597 DOI: 10.1016/j.cpet.2015.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Kim YI, Paeng JC, Cheon GJ, Suh KS, Lee DS, Chung JK, Kang KW. Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT. J Nucl Med. 2016;57:1045-1051. [PMID: 26985057 DOI: 10.2967/jnumed.115.170076] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
35 Rani SD, Nemanich ST, Fettig N, Shoghi KI. Kinetic analysis of FDG in rat liver: effect of dietary intervention on arterial and portal vein input. Nucl Med Biol 2013;40:537-46. [PMID: 23454249 DOI: 10.1016/j.nucmedbio.2013.01.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
36 Çelebi F, Yaghouti K, Cindil E, Dogusoy GB, Tokat Y, Balcı C. The Role of 18F-FDG PET/MRI in the Assessment of Primary Intrahepatic Neoplasms. Acad Radiol 2021;28:189-98. [PMID: 32111468 DOI: 10.1016/j.acra.2020.01.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Heits N, Brosch M, Herrmann A, Behrens R, Röcken C, Schrem H, Kaltenborn A, Klempnauer J, Kreipe HH, Reichert B, Lenschow C, Wilms C, Vogel T, Wolters H, Wardelmann E, Seehofer D, Buch S, Zeissig S, Pannach S, Raschzok N, Dietel M, von Schoenfels W, Hinz S, Teufel A, Evert M, Franke A, Becker T, Braun F, Hampe J, Schafmayer C. Evolutionary Distance Predicts Recurrence After Liver Transplantation in Multifocal Hepatocellular Carcinoma. Transplantation 2018;102:e424-30. [PMID: 29994984 DOI: 10.1097/TP.0000000000002356] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Kim YK, Lee KW, Cho SY, Han SS, Kim SH, Kim SK, Park SJ. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl. 2010;16:767-772. [PMID: 20517911 DOI: 10.1002/lt.22069] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
39 Jeong Y, Shin M, Yoon SM, Song G, Kim K, Ahn C, Moon D, Hwang S, Park J, Kim JH, Lee S. Liver Transplantation After Transarterial Chemoembolization and Radiotherapy for Hepatocellular Carcinoma with Vascular Invasion. J Gastrointest Surg 2017;21:275-83. [DOI: 10.1007/s11605-016-3302-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
40 Wang ZF, Fan XX, Xu M, Chen MJ, Zhao ZW, Zhou JD, Tu JF, Song JJ, Hu XH, Lu CY, Wu FZ, Zhang DK, Chen L, Liu L, Ying XH, Xu XF, Ji JS. Evaluation of the blood supply and efficacy of transcatheter arterial chemoembolization for patients with liver metastasis using 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Tumour Biol 2017;39:1010428317701656. [PMID: 28475013 DOI: 10.1177/1010428317701656] [Reference Citation Analysis]
41 Lin CY, Liao CW, Chu LY, Yen KY, Jeng LB, Hsu CN, Lin CL, Kao CH. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation. Clin Nucl Med. 2017;42:e183-e187. [PMID: 28114226 DOI: 10.1097/rlu.0000000000001545] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
42 Fraum TJ, Ludwig DR, Hope TA, Fowler KJ. PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects. Gastroenterol Clin North Am 2018;47:691-714. [PMID: 30115444 DOI: 10.1016/j.gtc.2018.04.011] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
43 Lerut J, Lai Q. Morphology does not tell us the entire story: biological behavior improves our ability to select patients with hepatocellular carcinoma waiting for liver transplantation. Hepatobiliary Pancreat Dis Int 2015;14:570-1. [PMID: 26663003 DOI: 10.1016/s1499-3872(15)60028-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Cho KJ, Choi NK, Shin MH, Chong AR. Clinical usefulness of FDG-PET in patients with hepatocellular carcinoma undergoing surgical resection. Ann Hepatobiliary Pancreat Surg. 2017;21:194-198. [PMID: 29264581 DOI: 10.14701/ahbps.2017.21.4.194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
45 Song GW, Hwang S, Lee SG. [Liver transplantation in patients with hepatocellular carcinoma]. Korean J Gastroenterol. 2010;55:350-360. [PMID: 20571302 DOI: 10.4166/kjg.2010.55.6.350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Shiomi S, Kawabe J. Clinical applications of positron emission tomography in hepatic tumors. Hepatol Res. 2011;41:611-617. [PMID: 21711419 DOI: 10.1111/j.1872-034x.2011.00819.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
47 Longo V, Brunetti O, D’oronzo S, Ostuni C, Gatti P, Silvestris F. Bone metastases in hepatocellular carcinoma: an emerging issue. Cancer Metastasis Rev 2014;33:333-42. [DOI: 10.1007/s10555-013-9454-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
48 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
49 Wu YC, Hsieh TC, Sun SS, Yen KY, Kao CH. Bilateral breast uptake demonstrated on FDG PET/CT scans in 3 male patients with hepatocellular carcinomas. Clin Nucl Med 2012;37:520-1. [PMID: 22475911 DOI: 10.1097/RLU.0b013e31823ea993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
50 Jadvar H. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: Potential role of other positron emission tomography radiotracers. Semin Nucl Med. 2012;42:247-254. [PMID: 22681673 DOI: 10.1053/j.semnuclmed.2012.02.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
51 Risse JH, Pauleit D, Bender H, Rabe C, Fischer H, Biersack H, Bucerius J. 18 F-FDG-PET and Histopathology in 131 I-Lipiodol Treatment for Primary Liver Cancer. Cancer Biotherapy and Radiopharmaceuticals 2009;24:445-52. [DOI: 10.1089/cbr.2008.0560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
52 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
53 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
54 Suh KS, Cho EH, Lee HW, Shin WY, Yi NJ, Lee KU. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis. 2007;25:329-333. [PMID: 17960068 DOI: 10.1159/000106913] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
55 Kornberg A, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. Sci Rep. 2017;7:14176. [PMID: 29074969 DOI: 10.1038/s41598-017-14430-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
56 Lee HW, Suh K. Advancements of liver transplantation for hepatocellular carcinoma in Korea. Japanese Journal of Clinical Oncology 2017;47:93-100. [DOI: 10.1093/jjco/hyw168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
57 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 9.5] [Reference Citation Analysis]
58 Arbizu J, de la Cruz R, Garrastachu P, Mitjavila M. [Liver disease: imaging techniques and new therapies]. Rev Esp Med Nucl 2009;28:135-57. [PMID: 19558957 DOI: 10.1016/s0212-6982(09)71359-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Hao B, Guo W, Luo NN, Fu H, Chen HJ, Zhao L, Wu H, Sun L. Metabolic imaging for guidance of curative treatment of isolated pelvic implantation metastasis after resection of spontaneously ruptured hepatocellular carcinoma: A case report. World J Gastroenterol 2016; 22(41): 9242-9246 [PMID: 27895412 DOI: 10.3748/wjg.v22.i41.9242] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
60 Kornberg A, Friess H. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches. Therap Adv Gastroenterol 2019;12:1756284819836205. [PMID: 30915167 DOI: 10.1177/1756284819836205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Hsu CC, Chen CL, Wang CC, Lin CC, Yong CC, Wang SH, Liu YW, Lin TL, Lee WF, Lin YH, Chan YC, Wu YJ, Eng HL, Cheng YF. Combination of FDG-PET and UCSF Criteria for Predicting HCC Recurrence After Living Donor Liver Transplantation. Transplantation. 2016;100:1925-1932. [PMID: 27306534 DOI: 10.1097/tp.0000000000001297] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
62 Kim Y, Kim SH, Lee S, Lee S, Park S. Pretransplant absolute monocyte count in peripheral blood predicts posttransplant tumor prognosis in patients undergoing liver transplantation for hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2014;13:250-8. [DOI: 10.1016/s1499-3872(14)60251-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation: Monitoring Patients with Hepatocellular Carcinoma. Liver Transpl 2011;17:S117-27. [DOI: 10.1002/lt.22334] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
64 Song HJ, Cheng JY, Hu SL, Zhang GY, Fu Y, Zhang YJ. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol. 2015;70:128-137. [PMID: 25459673 DOI: 10.1016/j.crad.2014.09.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
65 von Falck C, Rodt T, Shin H, Knapp WH, Galanski M. F-18 FDG PET Imaging of Fibrolamellar Hepatocellular Carcinoma. Clinical Nuclear Medicine 2008;33:633-4. [DOI: 10.1097/rlu.0b013e318181305c] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
66 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 685] [Article Influence: 57.0] [Reference Citation Analysis]
67 Pinilla I, Rodríguez-Vigil B, Gómez-León N. Integrated FDG PET/CT: Utility and Applications in Clinical Oncology. Clin Med Oncol 2008;2:181-98. [PMID: 21892279 DOI: 10.4137/cmo.s504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
68 Klasen J, Heusner T, Riegger C, Reichelt D, Kuhlemann J, Antoch G, Blondin D. Moderne CT- und PET/CT-Bildgebung der Leber. Radiologe 2011;51:671-9. [DOI: 10.1007/s00117-010-2125-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
69 Lee JW, Paeng JC, Kang KW, Kwon HW, Suh K, Chung J, Lee MC, Lee DS. Prediction of Tumor Recurrence by 18 F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma. J Nucl Med 2009;50:682-7. [DOI: 10.2967/jnumed.108.060574] [Cited by in Crossref: 118] [Cited by in F6Publishing: 108] [Article Influence: 9.1] [Reference Citation Analysis]
70 Mocherla B, Kim J, Roayaie S, Kim S, Machac J, Kostakoglu L. FDG PET/CT imaging to rule out extrahepatic metastases before liver transplantation. Clin Nucl Med. 2007;32:947-948. [PMID: 18030049 DOI: 10.1097/rlu.0b013e3181598cef] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
71 Yi NJ, Suh KS, Lee HW, Shin WY, Kim J, Kim W, Kim YJ, Yoon JH, Lee HS, Lee KU. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft. Liver Transpl. 2009;15:496-503. [PMID: 19399732 DOI: 10.1002/lt.21606] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
72 Kim MJ, Kim YS, Cho YH, Jang HY, Song JY, Lee SH, Jeong SW, Kim SG, Jang JY, Kim HS, Kim BS, Lee WH, Park JM, Lee JM, Lee MH, Choi DL. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Intern Med. 2015;30:308-315. [PMID: 25995661 DOI: 10.3904/kjim.2015.30.3.308] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
73 De Gaetano AM, Rufini V, Castaldi P, Gatto AM, Filograna L, Giordano A, Bonomo L. Clinical applications of 18F-FDG PET in the management of hepatobiliary and pancreatic tumors. Abdom Imaging 2012;37:983-1003. [DOI: 10.1007/s00261-012-9845-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
74 Lee SD, Kim SH, Kim YK, Kim C, Kim SK, Han SS, Park SJ. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2013;26:50-60. [PMID: 23106431 DOI: 10.1111/j.1432-2277.2012.01572.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
75 Dubash SR, Idowu OA, Sharma R. The emerging role of positron emission tomography in hepatocellular carcinoma. Hepat Oncol. 2015;2:191-200. [PMID: 30190998 DOI: 10.2217/hep.15.6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
76 Horvat N, Monti S, Oliveira BC, Rocha CCT, Giancipoli RG, Mannelli L. State of the art in magnetic resonance imaging of hepatocellular carcinoma. Radiol Oncol. 2018;52:353-364. [PMID: 30511939 DOI: 10.2478/raon-2018-0044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
77 Kitajima T, Hashimoto M, Sasaki K, Matsuda M, Kuroda Y, Fujii T, Watanabe G. Long-term survival after two surgical resections of peritoneal metastases from hepatocellular carcinoma with an interval of 4 years. Clin Case Rep 2014;2:37-41. [PMID: 25356240 DOI: 10.1002/ccr3.50] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Ye YF, Wang W, Wang T, Yu J, Geng L, Yu SF, Yan S, Zheng SS. Role of [18F] fludeoxyglucose positron emission tomography in the selection of liver transplantation candidates in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2017;16:257-263. [PMID: 28603093 DOI: 10.1016/s1499-3872(17)60011-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
79 Sandrasegaran K, Tahir B, Patel A, Ramaswamy R, Bertrand K, Akisik FM, Saxena R. The usefulness of diffusion-weighted imaging in the characterization of liver lesions in patients with cirrhosis. Clin Radiol. 2013;68:708-715. [PMID: 23510619 DOI: 10.1016/j.crad.2012.10.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
80 Bailly M, Venel Y, Orain I, Salamé E, Ribeiro MJ. 18F-FDG PET in Liver Transplantation Setting of Hepatocellular Carcinoma: Predicting Histology? Clin Nucl Med 2016;41:e126-9. [PMID: 26545024 DOI: 10.1097/RLU.0000000000001040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
81 Ling LL, Hsu C, Yong C, Elsarawy AM, Chan Y, Wang C, Li W, Lin T, Kuo F, Cheng Y, Lin L, Chen C, Lin C. FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study. International Journal of Surgery 2019;69:124-31. [DOI: 10.1016/j.ijsu.2019.07.035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
82 Sun L, Wu H, Pan WM, Guan YS. Positron emission tomography/computed tomography with 18F-fluorodeoxyglucose identifies tumor growth or thrombosis in the portal vein with hepatocellular carcinoma. World J Gastroenterol 2007; 13(33): 4529-4532 [PMID: 17724816 DOI: 10.3748/wjg.v13.i33.4529] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
83 Sun DW, An L, Wei F, Mu L, Shi XJ, Wang CL, Zhao ZW, Li TF, Lv GY. Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis. Abdom Radiol (NY). 2016;41:33-41. [PMID: 26830609 DOI: 10.1007/s00261-015-0603-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
84 Pant V, Sen IB, Soin AS. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma. Nucl Med Commun 2013;34:749-57. [PMID: 23689586 DOI: 10.1097/MNM.0b013e3283622eef] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
85 Fortune BE, Umman V, Gilliland T, Emre S. Liver transplantation for hepatocellular carcinoma: a surgical perspective. J Clin Gastroenterol 2013;47 Suppl:S37-42. [PMID: 23632344 DOI: 10.1097/MCG.0b013e318286ff8e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
86 Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018; 10(10): 336-343 [PMID: 30364796 DOI: 10.4251/wjgo.v10.i10.336] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
87 Asman Y, Evenson AR, Even-Sapir E, Shibolet O. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma. Liver Transpl. 2015;21:572-580. [PMID: 25644857 DOI: 10.1002/lt.24083] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
88 Talbot J, Montravers F, Gutman F, Kerrou K, Huchet V, Grahek D, Andre T, Houry S, Touboul E, Rosmorduc O, Poupon R, Ruszniewski P, Rougier P, Grange J. Tomographie par émission de positons et cancers digestifs. La Presse Médicale 2008;37:e1-e24. [DOI: 10.1016/j.lpm.2007.03.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
89 Suh KS, Lee HW. Liver transplantation for advanced hepatocellular carcinoma: how far can we go? Hepat Oncol 2015;2:19-28. [PMID: 30190984 DOI: 10.2217/hep.14.34] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
90 Kim JM, Kwon CHD, Joh JW, Sinn DH, Choi GS, Paik SW. Prognosis of preoperative positron emission tomography uptake in hepatectomy patients. Ann Surg Treat Res. 2018;94:183-189. [PMID: 29629352 DOI: 10.4174/astr.2018.94.4.183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
91 Lee S, Ahn C, Ha T, Moon D, Choi K, Song G, Chung D, Park G, Yu Y, Choi N, Kim K, Kim K, Hwang S. Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Sci. 2010;17:539-547. [PMID: 19727542 DOI: 10.1007/s00534-009-0167-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
92 Sun L, Wu H, Guan YS. Positron emission tomography/computer tomography: Challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 2007; 13(20): 2775-2783 [PMID: 17569111 DOI: 10.3748/wjg.v13.i20.2775] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
93 Lee JM, Park KM, Lee SY, Choi J, Hwang DW, Lee YJ. Metastasis of hepatocellular carcinoma to the ovary: a case report and review of the literature. Gut Liver 2011;5:543-7. [PMID: 22195258 DOI: 10.5009/gnl.2011.5.4.543] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
94 Kim K, Kim SJ. Diagnostic test accuracies of F-18 FDG PET/CT for prediction of microvascular invasion of hepatocellular carcinoma: A meta-analysis. Clin Imaging 2021;79:251-8. [PMID: 34157501 DOI: 10.1016/j.clinimag.2021.06.015] [Reference Citation Analysis]
95 Lee S, Kim KW, Song GW, Kwon JH, Hwang S, Kim KH, Ahn CS, Moon DB, Park GC, Lee SG. The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma. Liver Cancer 2020;9:721-33. [PMID: 33442541 DOI: 10.1159/000507887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Shin WY, Suh KS, Lee HW, Kim J, Kim T, Yi NJ, Uk Lee K. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2010;16: :678-684. [PMID: 20440777 DOI: 10.1002/lt.22047] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
97 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 183] [Article Influence: 15.2] [Reference Citation Analysis]
98 Tahir B, Sandrasegaran K, Ramaswamy R, Bertrand K, Mhapsekar R, Akisik FM, Saxena R. Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade? Clin Radiol 2011;66:845-52. [PMID: 21771548 DOI: 10.1016/j.crad.2011.03.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
99 Kornberg A, Küpper B, Tannapfel A, Büchler P, Krause B, Witt U, Gottschild D, Friess H. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl. 2012;18:53-61. [PMID: 21850692 DOI: 10.1002/lt.22416] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis]
100 Lee HW, Suh KS. Liver transplantation for advanced hepatocellular carcinoma. Clin Mol Hepatol 2016;22:309-18. [PMID: 27729631 DOI: 10.3350/cmh.2016.0042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
101 Kang Y, Choi JY, Paeng JC, Kim Y, Kwon HW, Cheon GJ, Suh K, Kwon CHD, Lee DS, Kang KW. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation. Eur Radiol 2019;29:6009-17. [DOI: 10.1007/s00330-019-06239-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
102 Hwang S, Ahn C, Kim K, Moon D, Ha T, Song G, Jung D, Park G, Yu Y, Park P, Choi Y, Kim K, Lim Y, Lee HC, Yu E, Lee S. Super-selection of a Subgroup of Hepatocellular Carcinoma Patients at Minimal Risk of Recurrence for Liver Transplantation. J Gastrointest Surg 2011;15:971-81. [DOI: 10.1007/s11605-011-1467-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
103 Yang Z, Luo FZ, Wang S, Lerut J, Zhuang L, Li QY, Xu X, Zheng SS. Alpha-fetoprotein and 18F-FDG standard uptake value predict tumor recurrence after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis: Preliminary experience. Hepatobiliary Pancreat Dis Int 2020;19:229-34. [PMID: 32303439 DOI: 10.1016/j.hbpd.2020.03.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Wang HY, Jeng LB, Lin MC, Chao CH, Lin WY, Kao CH. 18F-FDG PET/CT in detection of gynecomastia in patients with hepatocellular carcinoma. Clin Imaging 2013;37:942-6. [PMID: 23809917 DOI: 10.1016/j.clinimag.2013.01.004] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
105 Cascales-campos PA, Romero PR, Schneider MA, Lopez-lopez V, Navarro JL, Frutos L, Pons Miñano JA, Paricio PP. Positron emission tomography/computed tomography in patients with hepatocellular carcinoma undergoing liver transplantation. Useful, necessary or irrelevant? European Journal of Radiology 2017;91:155-9. [DOI: 10.1016/j.ejrad.2017.03.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
106 Rudolphi-solero T, Triviño-ibáñez EM, Medina-benítez A, Fernández-fernández J, Rivas-navas DJ, Pérez-alonso AJ, Gómez-río M, Aroui-luquin T, Rodríguez-fernández A. Differential Diagnosis of Hepatic Mass with Central Scar: Focal Nodular Hyperplasia Mimicking Fibrolamellar Hepatocellular Carcinoma. Diagnostics 2022;12:44. [DOI: 10.3390/diagnostics12010044] [Reference Citation Analysis]